A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo- and active-controlled, parallel group study will
evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute
exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg
or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients,
with a 4-week follow-up period.